Selection and Sequencing of JAK Inhibitors for Patients With MF

Author(s):

Andrew Kuykendall, MDRaajit K. Rampal, MD, PhD

Raajit K. Rampal, MD, PhD, discusses choosing among JAK inhibitors based on specific patient needs, such as platelet counts and anemia, emphasizing the importance of using the full dose for best efficacy and how different scenarios might influence the choice and sequencing of these drugs in practice.

EP: 1.How JAK Inhibitors Have Shaped the Landscape of MF

EP: 2.Pelabresib Plus Ruxolitinib for JAK Inhibitor-Naïve Patients: Data From MANIFEST and MANIFEST-2

EP: 3.Navitoclax Plus Ruxolitinib for Untreated MF: Data From TRANSFORM-1

EP: 4.Navtemadlin Plus Ruxolitinib for Patients With MF who had Suboptimal Responses to Ruxolitinib

EP: 5.Selinexor Plus Ruxolitinib in JAK Inhibitor-Naïve Patients: Updated Results From XPORT-MF-034

EP: 6.Luspatercept With or Without Ruxolitinib for the Treatment of Anemia in Patients With MF: Data From ACE-536-MF-001

EP: 7.Future Directions in Combination Therapies for Myelofibrosis

EP: 8.Key Efficacy and Safety Takeaways From Recent Data on JAK Inhibitors for MF

EP: 9.The FREEDOM-2 Trial: Efficacy and Safety of Fedratinib in Patients With MF Previously Treated With Ruxolitinib

Now Viewing